

Resource Summary Report

Generated by [RRID](#) on Aug 10, 2026

Phospho-EGF Receptor (Tyr1068) Antibody

RRID:AB_331701

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 2234, RRID:AB_331701

Antibody Information

URL: http://antibodyregistry.org/AB_331701

Proper Citation: Cell Signaling Technology Cat# 2234, RRID:AB_331701

Target Antigen: Phospho-EGF Receptor (Tyr1068)

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IHC-P. Consolidation on 9/2016: AB_331702. Info: Used By NYUIHC-360.

Info: Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:TRUE, Functional in animal:TRUE, NonFunctional in animal:FALSE

Antibody Name: Phospho-EGF Receptor (Tyr1068) Antibody

Description: This polyclonal targets Phospho-EGF Receptor (Tyr1068)

Target Organism: rat, h, m, mouse, r, human

Antibody ID: AB_331701

Vendor: Cell Signaling Technology

Catalog Number: 2234

Alternative Catalog Numbers: 2234S, 2234L

Record Creation Time: 20250820T053009+0000

Record Last Update: 20250820T214238+0000

Ratings and Alerts

- Independent validation by the NYU Lagone was performed for: IHC. This antibody was found to have the following characteristics: Functional in human:TRUE, NonFunctional in human:TRUE, Functional in animal:TRUE, NonFunctional in animal:FALSE - NYU Langone's Center for Biospecimen Research and Development <https://med.nyu.edu/research/scientific-cores-shared-resources/center-biospecimen-research-development>

No alerts have been found for Phospho-EGF Receptor (Tyr1068) Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 56 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Singh D, et al. (2026) Antibody-Mediated Targeting of Secretory Protein SCUBE3 Suppresses Cancer Progression by Inhibiting Oncogenic Signaling and Inducing Antitumor Immunity. Cancer research, 86(5), 1252.

Tan M, et al. (2026) A Novel Niclosamide Sulfate Prodrug with Enhanced Bioavailability Suppresses Hepatocellular Carcinoma via Inhibition of Multiple Signaling Pathways. bioRxiv : the preprint server for biology.

Lee EJ, et al. (2026) JIN-A02, a Mutant-Selective Fourth-Generation EGFR Inhibitor, Overcomes C797S-Mediated Resistance and Demonstrates Intracranial Activity in NSCLC. Clinical cancer research : an official journal of the American Association for Cancer Research, 32(9), 1835.

Savoca A, et al. (2026) Preclinical to Clinical Translation of Pharmacokinetic-Pharmacodynamic Relationship in EGFR Exon20Ins Mutations: A Modeling Framework for Irreversible Inhibitors. Molecular cancer therapeutics, 25(7), 1157.

Ma K, et al. (2026) ErbB family receptor dimerization dynamics and dysregulation via long-term single-molecule imaging. Cell, 189(11), 3413.

Buzo K, et al. (2026) WEE1 kinase inhibition to overcome acquired resistance to targeted therapies in colorectal cancer. EMBO molecular medicine, 18(6), 2322.

Liu Y, et al. (2026) A telomerase-SUCLG2 signaling axis drives drug resistance by protecting persister cells. Cell reports, 45(7), 117668.

Jeon YH, et al. (2026) Clinical and Molecular Characterization of a Rare EGFR cis Compound L833V/H835L Mutation in Non-Small Cell Lung Cancer. Cancer research

communications, 6(4), 913.

Yan Y, et al. (2025) Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer. *Advanced science* (Weinheim, Baden-Wurttemberg, Germany), 12(33), e03322.

Yonesaka K, et al. (2025) Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung Cancer. *Cells*, 14(6).

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Liu HM, et al. (2025) Neoadjuvant immunotherapy with or without chemotherapy in locally advanced oral squamous cell carcinoma: Randomized, two-arm, phase 2 trial. *Cell reports. Medicine*, 6(2), 101930.

Jain P, et al. (2025) Anthrax ET activates Rac1 and RTK signaling to induce F-actin reorganization and endothelial permeability. *iScience*, 28(11), 113682.

Chiu PH, et al. (2025) Therapeutic stress triggers tumor STAT1 acetylation to disarm immunotherapy. *Cell reports. Medicine*, 6(11), 102448.

Xu Y, et al. (2025) Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation. *Cell reports. Medicine*, 6(5), 102121.

Pagliarini RA, et al. (2025) STX-721, a Covalent EGFR/HER2 Exon 20 Inhibitor, Utilizes Exon 20-Mutant Dynamic Protein States and Achieves Unique Mutant Selectivity Across Human Cancer Models. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 31(14), 3002.

Sharma M, et al. (2024) Targeting DNA Repair and Survival Signaling in Diffuse Intrinsic Pontine Gliomas to Prevent Tumor Recurrence. *Molecular cancer therapeutics*, 23(1), 24.

Zutshi N, et al. (2024) Cbl and Cbl-b ubiquitin ligases are essential for intestinal epithelial stem cell maintenance. *iScience*, 27(6), 109912.

Thapa N, et al. (2024) A p85 isoform switch enhances PI3K activation on endosomes by a MAP4- and PI3P-dependent mechanism. *Cell reports*, 43(5), 114119.

Roy A, et al. (2024) Impact of Interleukin-6 Activation and Arthritis on Epidermal Growth Factor Receptor (EGFR) Activation in Sensory Neurons and the Spinal Cord. *International journal of molecular sciences*, 25(13).